Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DE |
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
921.7m EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
199.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
179.1B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
146.9B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.2B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
109.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.3B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
51.6B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.7B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -222 027.4% |
| 30th Percentile | -2% |
| Median | 2.2% |
| 70th Percentile | 6% |
| Max | 85 055.6% |
Other Profitability Ratios
Eckert & Ziegler Strahlen und Medizintechnik AG
Glance View
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Eckert & Ziegler Strahlen und Medizintechnik AG is 13.1%, which is above its 3-year median of 11.5%.
Over the last 3 years, Eckert & Ziegler Strahlen und Medizintechnik AG’s Net Margin has decreased from 13.4% to 13.1%. During this period, it reached a low of 10.6% on Sep 30, 2024 and a high of 13.4% on Sep 30, 2022.
